drugset / Trial / NCT01950299

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

NCT01950299

RandomizedParallel-groupQuadruple-blindTreatment

Summary

VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.

Timeline

Start
2014-07-01
Primary completion
2018-12-23
Completion
2018-12-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg